BioCentury
ARTICLE | Finance

X marks the spot for Atlas

Now life sciences-only, what VC Atlas plans to do with $280M Fund X

April 20, 2015 7:00 AM UTC

With last week's close of its oversubscribed $280 million tenth fund, Atlas Venture completed its transition into a solely life sciences-focused venture firm looking at early stage investments in therapeutics.

Atlas was a hybrid focused on tech and life sciences. But in October, the firm said its teams would be stronger if they raised independent funds, citing diverging ecosystems and business models (see BioCentury, Oct. 6, 2014). ...